Showing 8031-8040 of 8822 results for "".
- Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-submits-marketing-authorization-application-in-europe-for-a-101-40-for-seborrheic-keratosis/2458100/Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis. The MPA will act as the reference member state in this decentraliz
- Modernizing Medicine To Add More Than 800 Jobs in Expansionhttps://practicaldermatology.com/news/modernizing-medicine-to-add-more-than-800-jobs-in-expansion/2458101/Modernizing Medicine will expand operations and add a total of 838 jobs by 2022. The expansion, to be implemented in the historic Boca Raton Innovation Center (BRIC) in Palm Beach County will result in a capital investment of more than $15 million in the Boca Raton community.
- FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanomahttps://practicaldermatology.com/news/fda-expands-approval-of-yervoy-to-include-pediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma/2458113/The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of pediatric patients:
- Paratek: Phase 3 Study of Oral-Only Dosing of Omadacycline Met FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infectionshttps://practicaldermatology.com/news/paratek-phase-3-study-of-oral-only-dosing-of-omadacycline-met-fda-and-ema-efficacy-endpoints-in-acute-bacterial-skin-infections/2458118/Paratek Pharmaceuticals, Inc. shared positive top-line results from a pivotal Phase 3 study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The study met all of
- Syneron Candela Completes Transaction with Funds Advised by Apax Partners; Becomes a Private Companyhttps://practicaldermatology.com/news/syneron-candela-completes-transaction-with-funds-advised-by-apax-partners-becomes-a-private-company/2458121/Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transacti
- Galderma CareConnect Patient Savings Card Program Passes Milestonehttps://practicaldermatology.com/news/galderma-careconnect-patient-savings-card-program-passes-milestone/2458119/The Galderma CareConnect patient savings program has surpassed the mark of 1,000,000 prescriptions filled through its patient access program. Committed to keeping accessibility remarkably simple and saving patients’ money, the company says the program is structured to work at any accredited
- Tomatoes May Slash Skin Cancer Riskhttps://practicaldermatology.com/news/tomatoes-may-slash-skin-cancer-risk/2458122/Daily tomato consumption may cut skin cancer risk in half, according to a new study in mice. The Ohio State University researchers report their findings online in the journal
- FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-for-moderate-to-severe-plaque-psoriasis/2458123/The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a
- Derms Urged to Step Up Role in Antibiotic Stewardshiphttps://practicaldermatology.com/news/derms-urged-to-step-up-role-in-antibiotic-stewardship/2458126/Dermatologists can and should play a larger role in antibiotic stewardship, according to researchers out of Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Data from the CDC shows the average dermatology provider wrote 669 antibiotic prescriptions in 2014, t
- Samsung Biologics to Manufacture Sun Pharma's Tildrakizumab for Psoriasishttps://practicaldermatology.com/news/samsung-biologics-to-manufacture-sun-pharmas-tildrakizumab-for-psoriasis/2458130/Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is currently under review by the US Food & Drug Admi